In vitro evaluation of the haemostatic value of the LFB‐von Willebrand factor concentrate
Identifieur interne : 000068 ( Istex/Corpus ); précédent : 000067; suivant : 000069In vitro evaluation of the haemostatic value of the LFB‐von Willebrand factor concentrate
Auteurs : MazurierSource :
- Haemophilia [ 1351-8216 ] ; 1998-11.
English descriptors
- Teeft :
- Agarose, Assay, Blackwell science, Cofactor, Cryoprecipitate, Different fractions, Different lots, Electrophoretic, Factor viii, Functional integrity, Fviii, Goudemand, Haemophilia, Haemostatic, Haemostatic value, High purity, Laboratoire francais, Mazurier, Multimeric, Multimeric pattern, Multimers, Native plasma, Normal plasmas, Platelet, Platelet adhesion, Preclinical, Preclinical development, Quality control, Quantitative evaluation, Rectangular perfusion chamber system, Ristocetin, Ristocetin cofactor activity, Suppl, Therapeutic lots, Thromb, Thromb haemost, Various multimers, Viii, Willebrand, Willebrand disease, Willebrand disease patients, Willebrand factor.
Abstract
The structural and functional studies of the concentrate of von Willebrand factor (vWF) manufactured by LFB have been first performed as part of the preclinical development of this product specially intended for the treatment of von Willebrand disease. The electrophoretic analyses showed the high purity of LFB‐vWF concentrate (specific activity of 100 IU of ristocetin cofactor activity per milligram of protein) and the multimeric pattern attesting the presence of high molecular weight multimeters (≥15‐mers). The measurements of vWF capacity to bind to: (1) platelet glycoprotein (GP) Ib in the presence of ristocetin; (2) GPIIb/IIIa in the presence of thrombin; (3) types I and III collagen; (4) factor VIII (FVIII) gave evidence that the functional activity of purified vWF was similar to that of native plasma vWF. Furthermore the LFB‐vWF concentrate was able to promote platelet adhesion to collagen. The release of the therapeutic batches of this product rely presently on their potency measured with the ristocetin cofactor activity (40–70 IU ml−1) and the quantitative evaluation of vWF multimeric distribution studied using electrophoresis in 1.5% agarose. These validated techniques ensure the consistency and haemostatic properties of the different lots of LFB‐vWF concentrate.
Url:
DOI: 10.1046/j.1365-2516.1998.0040s3040.x
Links to Exploration step
ISTEX:A426110A51A47360E86467CF7D76CAFD62D6DBCCLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">In vitro evaluation of the haemostatic value of the LFB‐von Willebrand factor concentrate</title><author><name sortKey="Mazurier" sort="Mazurier" uniqKey="Mazurier" first="" last="Mazurier">Mazurier</name><affiliation><mods:affiliation>Unité de Développement Pré‐Clinique, Laboratoire Français du Fractionnement et des Biotechnologies, Lille, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A426110A51A47360E86467CF7D76CAFD62D6DBCC</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1046/j.1365-2516.1998.0040s3040.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-SRXBTGD4-5/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000068</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000068</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">In vitro evaluation of the haemostatic value of the LFB‐von Willebrand factor concentrate</title><author><name sortKey="Mazurier" sort="Mazurier" uniqKey="Mazurier" first="" last="Mazurier">Mazurier</name><affiliation><mods:affiliation>Unité de Développement Pré‐Clinique, Laboratoire Français du Fractionnement et des Biotechnologies, Lille, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Haemophilia</title><title level="j" type="alt">HAEMOPHILIA</title><idno type="ISSN">1351-8216</idno><idno type="eISSN">1365-2516</idno><imprint><biblScope unit="vol">4</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="page" from="40">40</biblScope><biblScope unit="page" to="43">43</biblScope><biblScope unit="page-count">4</biblScope><publisher>Blackwell Science Ltd</publisher><pubPlace>Oxford UK</pubPlace><date type="published" when="1998-11">1998-11</date></imprint><idno type="ISSN">1351-8216</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-8216</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Agarose</term><term>Assay</term><term>Blackwell science</term><term>Cofactor</term><term>Cryoprecipitate</term><term>Different fractions</term><term>Different lots</term><term>Electrophoretic</term><term>Factor viii</term><term>Functional integrity</term><term>Fviii</term><term>Goudemand</term><term>Haemophilia</term><term>Haemostatic</term><term>Haemostatic value</term><term>High purity</term><term>Laboratoire francais</term><term>Mazurier</term><term>Multimeric</term><term>Multimeric pattern</term><term>Multimers</term><term>Native plasma</term><term>Normal plasmas</term><term>Platelet</term><term>Platelet adhesion</term><term>Preclinical</term><term>Preclinical development</term><term>Quality control</term><term>Quantitative evaluation</term><term>Rectangular perfusion chamber system</term><term>Ristocetin</term><term>Ristocetin cofactor activity</term><term>Suppl</term><term>Therapeutic lots</term><term>Thromb</term><term>Thromb haemost</term><term>Various multimers</term><term>Viii</term><term>Willebrand</term><term>Willebrand disease</term><term>Willebrand disease patients</term><term>Willebrand factor</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The structural and functional studies of the concentrate of von Willebrand factor (vWF) manufactured by LFB have been first performed as part of the preclinical development of this product specially intended for the treatment of von Willebrand disease. The electrophoretic analyses showed the high purity of LFB‐vWF concentrate (specific activity of 100 IU of ristocetin cofactor activity per milligram of protein) and the multimeric pattern attesting the presence of high molecular weight multimeters (≥15‐mers). The measurements of vWF capacity to bind to: (1) platelet glycoprotein (GP) Ib in the presence of ristocetin; (2) GPIIb/IIIa in the presence of thrombin; (3) types I and III collagen; (4) factor VIII (FVIII) gave evidence that the functional activity of purified vWF was similar to that of native plasma vWF. Furthermore the LFB‐vWF concentrate was able to promote platelet adhesion to collagen. The release of the therapeutic batches of this product rely presently on their potency measured with the ristocetin cofactor activity (40–70 IU ml−1) and the quantitative evaluation of vWF multimeric distribution studied using electrophoresis in 1.5% agarose. These validated techniques ensure the consistency and haemostatic properties of the different lots of LFB‐vWF concentrate.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>willebrand</json:string><json:string>platelet</json:string><json:string>multimers</json:string><json:string>willebrand factor</json:string><json:string>willebrand disease</json:string><json:string>mazurier</json:string><json:string>ristocetin</json:string><json:string>multimeric</json:string><json:string>agarose</json:string><json:string>viii</json:string><json:string>electrophoretic</json:string><json:string>haemostatic</json:string><json:string>haemophilia</json:string><json:string>normal plasmas</json:string><json:string>cofactor</json:string><json:string>ristocetin cofactor activity</json:string><json:string>preclinical development</json:string><json:string>multimeric pattern</json:string><json:string>thromb</json:string><json:string>fviii</json:string><json:string>blackwell science</json:string><json:string>suppl</json:string><json:string>goudemand</json:string><json:string>cryoprecipitate</json:string><json:string>preclinical</json:string><json:string>assay</json:string><json:string>thromb haemost</json:string><json:string>quantitative evaluation</json:string><json:string>factor viii</json:string><json:string>platelet adhesion</json:string><json:string>quality control</json:string><json:string>willebrand disease patients</json:string><json:string>functional integrity</json:string><json:string>different lots</json:string><json:string>rectangular perfusion chamber system</json:string><json:string>different fractions</json:string><json:string>therapeutic lots</json:string><json:string>high purity</json:string><json:string>various multimers</json:string><json:string>laboratoire francais</json:string><json:string>haemostatic value</json:string><json:string>native plasma</json:string></teeft></keywords><author><json:item><name>Mazurier Mazurier</name><affiliations><json:string>Unité de Développement Pré‐Clinique, Laboratoire Français du Fractionnement et des Biotechnologies, Lille, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>von Willebrand factor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>von Willebrand disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>ristocetin cofactor activity</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>multimers</value></json:item></subject><articleId><json:string>HAE9</json:string></articleId><arkIstex>ark:/67375/WNG-SRXBTGD4-5</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>The structural and functional studies of the concentrate of von Willebrand factor (vWF) manufactured by LFB have been first performed as part of the preclinical development of this product specially intended for the treatment of von Willebrand disease. The electrophoretic analyses showed the high purity of LFB‐vWF concentrate (specific activity of 100 IU of ristocetin cofactor activity per milligram of protein) and the multimeric pattern attesting the presence of high molecular weight multimeters (≥15‐mers). The measurements of vWF capacity to bind to: (1) platelet glycoprotein (GP) Ib in the presence of ristocetin; (2) GPIIb/IIIa in the presence of thrombin; (3) types I and III collagen; (4) factor VIII (FVIII) gave evidence that the functional activity of purified vWF was similar to that of native plasma vWF. Furthermore the LFB‐vWF concentrate was able to promote platelet adhesion to collagen. The release of the therapeutic batches of this product rely presently on their potency measured with the ristocetin cofactor activity (40–70 IU ml−1) and the quantitative evaluation of vWF multimeric distribution studied using electrophoresis in 1.5% agarose. These validated techniques ensure the consistency and haemostatic properties of the different lots of LFB‐vWF concentrate.</abstract><qualityIndicators><refBibsNative>true</refBibsNative><abstractWordCount>191</abstractWordCount><abstractCharCount>1292</abstractCharCount><keywordCount>4</keywordCount><score>6.02</score><pdfWordCount>1728</pdfWordCount><pdfCharCount>11241</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>4</pdfPageCount><pdfPageSize>595 x 782 pts</pdfPageSize><pdfWordsPerPage>432</pdfWordsPerPage><pdfText>true</pdfText></qualityIndicators><title>In vitro evaluation of the haemostatic value of the LFB‐von Willebrand factor concentrate</title><pmid><json:string>10028317</json:string></pmid><genre><json:string>article</json:string></genre><host><title>Haemophilia</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1365-2516</json:string></doi><issn><json:string>1351-8216</json:string></issn><eissn><json:string>1365-2516</json:string></eissn><publisherId><json:string>HAE</json:string></publisherId><volume>4</volume><issue>S3</issue><pages><first>40</first><last>43</last><total>4</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1997</json:string><json:string>1998</json:string><json:string>1989</json:string></date><geogName></geogName><orgName></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName></persName><placeName><json:string>France</json:string><json:string>Lille</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>[12]</json:string><json:string>[6]</json:string><json:string>[8]</json:string><json:string>[10]</json:string><json:string>[7]</json:string><json:string>[9]</json:string><json:string>[4,5]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-SRXBTGD4-5</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - hematology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - cardiovascular system & hematology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Genetics(clinical)</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Hematology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - General Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - hemopathies</json:string></inist></categories><publicationDate>1998</publicationDate><copyrightDate>1998</copyrightDate><doi><json:string>10.1046/j.1365-2516.1998.0040s3040.x</json:string></doi><id>A426110A51A47360E86467CF7D76CAFD62D6DBCC</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-SRXBTGD4-5/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-SRXBTGD4-5/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-SRXBTGD4-5/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">In vitro evaluation of the haemostatic value of the LFB‐von Willebrand factor concentrate</title><title level="a" type="short">IN VITRO EVALUATION OF LFB‐vWF CONCENTRATED</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Science Ltd</publisher><pubPlace>Oxford UK</pubPlace><date type="published" when="1998-11"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">In vitro evaluation of the haemostatic value of the LFB‐von Willebrand factor concentrate</title><title level="a" type="short">IN VITRO EVALUATION OF LFB‐vWF CONCENTRATED</title><author xml:id="author-0000"><persName><surname>Mazurier</surname></persName><affiliation><orgName type="laboratory">Unité de Développement Pré‐Clinique</orgName><orgName type="laboratory">Laboratoire Français du Fractionnement et des Biotechnologies</orgName><address><addrLine>Lille</addrLine><addrLine>France</addrLine><country key="FR" xml:lang="en">FRANCE</country></address></affiliation></author><idno type="istex">A426110A51A47360E86467CF7D76CAFD62D6DBCC</idno><idno type="ark">ark:/67375/WNG-SRXBTGD4-5</idno><idno type="DOI">10.1046/j.1365-2516.1998.0040s3040.x</idno><idno type="unit">HAE9</idno><idno type="toTypesetVersion">file:HAE.HAE9.pdf</idno></analytic><monogr><title level="j" type="main">Haemophilia</title><title level="j" type="alt">HAEMOPHILIA</title><idno type="pISSN">1351-8216</idno><idno type="eISSN">1365-2516</idno><idno type="book-DOI">10.1111/(ISSN)1365-2516</idno><idno type="book-part-DOI">10.1111/hae.1998.4.issue-S3</idno><idno type="product">HAE</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">4</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="page" from="40">40</biblScope><biblScope unit="page" to="43">43</biblScope><biblScope unit="page-count">4</biblScope><publisher>Blackwell Science Ltd</publisher><pubPlace>Oxford UK</pubPlace><date type="published" when="1998-11"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><p>The structural and functional studies of the concentrate of von Willebrand factor (vWF) manufactured by LFB have been first performed as part of the preclinical development of this product specially intended for the treatment of von Willebrand disease. The electrophoretic analyses showed the high purity of LFB‐vWF concentrate (specific activity of 100 IU of ristocetin cofactor activity per milligram of protein) and the multimeric pattern attesting the presence of high molecular weight multimeters (≥15‐mers). The measurements of vWF capacity to bind to: (1) platelet glycoprotein (GP) Ib in the presence of ristocetin; (2) GPIIb/IIIa in the presence of thrombin; (3) types I and III collagen; (4) factor VIII (FVIII) gave evidence that the functional activity of purified vWF was similar to that of native plasma vWF. Furthermore the LFB‐vWF concentrate was able to promote platelet adhesion to collagen. The release of the therapeutic batches of this product rely presently on their potency measured with the ristocetin cofactor activity (40–70 IU ml<hi rend="superscript">−1</hi>) and the quantitative evaluation of vWF multimeric distribution studied using electrophoresis in 1.5% agarose. These validated techniques ensure the consistency and haemostatic properties of the different lots of LFB‐vWF concentrate.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">von Willebrand factor</term><term xml:id="k2">von Willebrand disease</term><term xml:id="k3">ristocetin cofactor activity</term><term xml:id="k4">multimers</term></keywords><keywords rend="tocHeading1"><term>Original Article</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-SRXBTGD4-5/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Science Ltd</publisherName><publisherLoc>Oxford UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1365-2516</doi><issn type="print">1351-8216</issn><issn type="electronic">1365-2516</issn><idGroup><id type="product" value="HAE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="HAEMOPHILIA">Haemophilia</title></titleGroup></publicationMeta><publicationMeta level="part" position="11003"><doi origin="wiley">10.1111/hae.1998.4.issue-S3</doi><numberingGroup><numbering type="journalVolume" number="4">4</numbering><numbering type="journalIssue">S3</numbering></numberingGroup><coverDate startDate="1998-11">November 1998</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="0004000" status="forIssue"><doi origin="wiley">10.1046/j.1365-2516.1998.0040s3040.x</doi><idGroup><id type="unit" value="HAE9"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="tocHeading1">Original Article</title></titleGroup><eventGroup><event type="firstOnline" date="2002-01-04"></event><event type="publishedOnlineFinalForm" date="2002-01-04"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:3.2.3 mode:FullText" date="2013-08-29"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-26"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-24"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="40">40</numbering><numbering type="pageLast" number="43">43</numbering></numberingGroup><correspondenceTo>Mazurier Unité de Développement Pré‐Clinique, Laboratoire Français Du Fractionnement et Des Biotechnologies, 59 Rue de Trévise, BP 2006, 59011 – Lille Cédex, France. Tel: +33 320 494480; Fax: +33 320 494471.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:HAE.HAE9.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="12"></count><count type="linksPubMed" number="0"></count><count type="linksCrossRef" number="0"></count></countGroup><titleGroup><title type="main"><i>In vitro</i> evaluation of the haemostatic value of the LFB‐von Willebrand factor concentrate</title><title type="shortAuthors">C. MAZURIER</title><title type="short">IN VITRO EVALUATION OF LFB‐vWF CONCENTRATED</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><familyName>Mazurier</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="FR"><unparsedAffiliation>Unité de Développement Pré‐Clinique, Laboratoire Français du Fractionnement et des Biotechnologies, Lille, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">von Willebrand factor</keyword><keyword xml:id="k2">von Willebrand disease</keyword><keyword xml:id="k3">ristocetin cofactor activity</keyword><keyword xml:id="k4">multimers</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p>The structural and functional studies of the concentrate of von Willebrand factor (vWF) manufactured by LFB have been first performed as part of the preclinical development of this product specially intended for the treatment of von Willebrand disease. The electrophoretic analyses showed the high purity of LFB‐vWF concentrate (specific activity of 100 IU of ristocetin cofactor activity per milligram of protein) and the multimeric pattern attesting the presence of high molecular weight multimeters (≥15‐mers). The measurements of vWF capacity to bind to: (1) platelet glycoprotein (GP) Ib in the presence of ristocetin; (2) GPIIb/IIIa in the presence of thrombin; (3) types I and III collagen; (4) factor VIII (FVIII) gave evidence that the functional activity of purified vWF was similar to that of native plasma vWF. Furthermore the LFB‐vWF concentrate was able to promote platelet adhesion to collagen. The release of the therapeutic batches of this product rely presently on their potency measured with the ristocetin cofactor activity (40–70 IU ml<sup>−1</sup>) and the quantitative evaluation of vWF multimeric distribution studied using electrophoresis in 1.5% agarose. These validated techniques ensure the consistency and haemostatic properties of the different lots of LFB‐vWF concentrate.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>In vitro evaluation of the haemostatic value of the LFB‐von Willebrand factor concentrate</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>IN VITRO EVALUATION OF LFB‐vWF CONCENTRATED</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>In vitro evaluation of the haemostatic value of the LFB‐von Willebrand factor concentrate</title></titleInfo><name type="personal"><namePart>Mazurier</namePart><namePart type="family">Mazurier</namePart><affiliation>Unité de Développement Pré‐Clinique, Laboratoire Français du Fractionnement et des Biotechnologies, Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Blackwell Science Ltd</publisher><place><placeTerm type="text">Oxford UK</placeTerm></place><dateIssued encoding="w3cdtf">1998-11</dateIssued><copyrightDate encoding="w3cdtf">1998</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">2</extent><extent unit="tables">0</extent><extent unit="references">12</extent><extent unit="linksCrossRef">0</extent></physicalDescription><abstract lang="en">The structural and functional studies of the concentrate of von Willebrand factor (vWF) manufactured by LFB have been first performed as part of the preclinical development of this product specially intended for the treatment of von Willebrand disease. The electrophoretic analyses showed the high purity of LFB‐vWF concentrate (specific activity of 100 IU of ristocetin cofactor activity per milligram of protein) and the multimeric pattern attesting the presence of high molecular weight multimeters (≥15‐mers). The measurements of vWF capacity to bind to: (1) platelet glycoprotein (GP) Ib in the presence of ristocetin; (2) GPIIb/IIIa in the presence of thrombin; (3) types I and III collagen; (4) factor VIII (FVIII) gave evidence that the functional activity of purified vWF was similar to that of native plasma vWF. Furthermore the LFB‐vWF concentrate was able to promote platelet adhesion to collagen. The release of the therapeutic batches of this product rely presently on their potency measured with the ristocetin cofactor activity (40–70 IU ml−1) and the quantitative evaluation of vWF multimeric distribution studied using electrophoresis in 1.5% agarose. These validated techniques ensure the consistency and haemostatic properties of the different lots of LFB‐vWF concentrate.</abstract><subject lang="en"><genre>keywords</genre><topic>von Willebrand factor</topic><topic>von Willebrand disease</topic><topic>ristocetin cofactor activity</topic><topic>multimers</topic></subject><relatedItem type="host"><titleInfo><title>Haemophilia</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">1351-8216</identifier><identifier type="eISSN">1365-2516</identifier><identifier type="DOI">10.1111/(ISSN)1365-2516</identifier><identifier type="PublisherID">HAE</identifier><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><detail type="issue"><caption>no.</caption><number>S3</number></detail><extent unit="pages"><start>40</start><end>43</end><total>4</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Clinical and biological evaluation in von Willebrand’s disease of a von Willebrand factor concentrate with low factor VIII activity</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Goudemand</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Mazurier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Marey</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Goudemand J, Mazurier C, Marey A et al. Clinical and biological evaluation in von Willebrand’s disease of a von Willebrand factor concentrate with low factor VIII activity. Br J Haematol 1992; 80: 214 21.</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>214</start><end>21</end></extent></part><relatedItem type="host"><titleInfo><title>Br J Haematol</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>214</start><end>21</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>A perspective on the use of FVIII concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with von Willebrand disease unresponsive to dDAVP. Results of an international survey</title></titleInfo><name type="personal"><namePart type="given">PA</namePart><namePart type="family">Foster</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Foster PA. A perspective on the use of FVIII concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with von Willebrand disease unresponsive to dDAVP. Results of an international survey. Thromb Haemost 1995; 74: 1370 8.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>74</number></detail><extent unit="pages"><start>1370</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Thromb Haemost</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>74</number></detail><extent unit="pages"><start>1370</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Continuous infusion therapy with very high purity von Willebrand factor concentrate in patients with severe von Willebrand disease</title></titleInfo><name type="personal"><namePart type="given">MP</namePart><namePart type="family">Smith</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KM</namePart><namePart type="family">Rice</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ES</namePart><namePart type="family">Bromidge</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Smith MP, Rice KM, Bromidge ES et al. Continuous infusion therapy with very high purity von Willebrand factor concentrate in patients with severe von Willebrand disease. Blood Coag Fib 1997; 8: 6 12.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>6</start><end>12</end></extent></part><relatedItem type="host"><titleInfo><title>Blood Coag Fib</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>6</start><end>12</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Burnouf‐Radosevich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Burnouf</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Burnouf‐Radosevich M & Burnouf T. Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate. Vox Sang 1992; 62: 1 11.</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>1</start><end>11</end></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>1</start><end>11</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Von Willebrand factor purification from human plasma cryoprecipitate</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Burnouf‐Radosevich</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Burnouf‐Radosevich M. Von Willebrand factor purification from human plasma cryoprecipitate. J Tissue Culture Meth 1994; 16: 223 6.</note><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>223</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>J Tissue Culture Meth</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>223</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>In vitro evaluation of a very‐high‐purity, solvent/detergent‐treated, von Willebrand factor concentrate</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Mazurier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Jorieux</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">de Romeuf</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Samor</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Goudemand</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mazurier C, Jorieux S, de Romeuf C, Samor B, Goudemand M. In vitro evaluation of a very‐high‐purity, solvent/detergent‐treated, von Willebrand factor concentrate. Vox Sang 1991; 61: 1 7.</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>1</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>1</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Improved characterization of plasma von Willebrand factor heterogeneity when using 2.5% agarose gel electrophoresis</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Mazurier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Samor</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Goudemand</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mazurier C, Samor B, Goudemand M. Improved characterization of plasma von Willebrand factor heterogeneity when using 2.5% agarose gel electrophoresis. Thromb Haemost 1986; 55: 61 4.</note><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>61</start><end>4</end></extent></part><relatedItem type="host"><titleInfo><title>Thromb Haemost</title></titleInfo><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>61</start><end>4</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>An ELISA test for the binding of von Willebrand antigen to collagen</title></titleInfo><name type="personal"><namePart type="given">JE</namePart><namePart type="family">Brown</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JO</namePart><namePart type="family">Bosak</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brown JE & Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res 1986; 43: 303 11.</note><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>303</start><end>11</end></extent></part><relatedItem type="host"><titleInfo><title>Thromb Res</title></titleInfo><part><date>1986</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>303</start><end>11</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Mazurier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Dieval</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Jorieux</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Delobel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Goudemand</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mazurier C, Dieval J, Jorieux S, Delobel J, Goudemand M. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction. Blood 1990; 75: 20 6.</note><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>20</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>20</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix and purified components</title></titleInfo><name type="personal"><namePart type="given">KS</namePart><namePart type="family">Sakariassen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Aarts</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">de Groot</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Houdijk</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JJ</namePart><namePart type="family">Sixma</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sakariassen KS, Aarts P, de Groot P, Houdijk W, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix and purified components. J Lab Clin Med 1983; 10: 522 35.</note><part><date>1983</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>522</start><end>35</end></extent></part><relatedItem type="host"><titleInfo><title>J Lab Clin Med</title></titleInfo><part><date>1983</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>522</start><end>35</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Recommended protocol for the study of the ex vivo biological effects of virus‐inactivated plasma concentrates in patients with von Willebrand disease</title></titleInfo><name type="personal"><namePart type="given">PM</namePart><namePart type="family">Mannucci</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mannucci PM. Recommended protocol for the study of the ex vivo biological effects of virus‐inactivated plasma concentrates in patients with von Willebrand disease. Thromb Haemost 1992; 68: 84 7.</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>84</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Thromb Haemost</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>84</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Quantitative assay of a plasma factor, deficient in von Willebrand’s disease, that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Weiss</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LW</namePart><namePart type="family">Hoyer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Rickles</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Varma</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Rogers</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Weiss H, Hoyer LW, Rickles F, Varma A, Rogers J. Quantitative assay of a plasma factor, deficient in von Willebrand’s disease, that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. J Clin Invest 1973; 52: 2708 16.</note><part><date>1973</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>2708</start><end>16</end></extent></part><relatedItem type="host"><titleInfo><title>J Clin Invest</title></titleInfo><part><date>1973</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>2708</start><end>16</end></extent></part></relatedItem></relatedItem><identifier type="istex">A426110A51A47360E86467CF7D76CAFD62D6DBCC</identifier><identifier type="ark">ark:/67375/WNG-SRXBTGD4-5</identifier><identifier type="DOI">10.1046/j.1365-2516.1998.0040s3040.x</identifier><identifier type="ArticleID">HAE9</identifier><accessCondition type="use and reproduction" contentType="copyright">© Wiley. All rights reserved.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-14</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-SRXBTGD4-5/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000068 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000068 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:A426110A51A47360E86467CF7D76CAFD62D6DBCC
|texte= In vitro evaluation of the haemostatic value of the LFB‐von Willebrand factor concentrate
}}
| This area was generated with Dilib version V0.6.33. |  |